Vaccination Of High Risk Breast Cancer Patients With Heptavalent Antigen - Keyhole Limpet Hemocyanin Conjugate Plus The Immunological Adjuvant QS21

NCT00030823 NA COMPLETED Results posted

RATIONALE: Vaccines may make the body build an immune response and decrease the recurrence of breast cancer. PURPOSE: Pilot trial to study the effectiveness of vaccine therapy in treating patients who are at high risk for breast cancer recurrence.

Details

Lead sponsor	Memorial Sloan Kettering Cancer Center
Phase	NA
Status	COMPLETED
Enrolment	14
Start date	2001-03
Completion	2009-02

Conditions

• Breast Cancer

Interventions

• Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine
• QS21

Primary outcomes

• Safety — 2 years
  By assessing the toxicity and will be graded following immunization with polyvalent vaccine in accordance with the NCI Common Toxicity Criteria 2.0.

Countries

United States